Enterprise Resilience for Life Sciences
A supplier, site, or quality failure can interrupt manufacturing, delay clinical programs, and constrain product supply at the same time. Fusion connects products to the materials, facilities, systems, contract partners, and teams behind them so leaders can understand impact and prioritize recovery at decision speed.
4.4/5 Star Rating on G2
Leader in BCM
BCI World Hall of Fame
4.5/5 Star Rating on Capterra
What Does Enterprise Resilience Mean for Life Sciences?
Enterprise resilience is the operating capability that allows a life sciences organization to quantify disruption exposure, protect product supply and clinical program continuity, and make confident decisions under disruption.
Supplier assessments, quality systems, and continuity plans each provide essential information. Fusion connects that information in a continuously curated service-and-dependency model that shows how products and programs depend on sites, materials, systems, partners, and teams. When disruption occurs, leaders can understand the downstream impact and coordinate the right response at decision speed.
Concentration Changes Across the Supply Chain
Pharmaceutical supply risk does not concentrate in the same country at every tier. India and the European Union supply much of the active pharmaceutical ingredient volume used by U.S. prescription medicines, while China remains a significant upstream source of key starting materials.
That distinction matters. A product can draw ingredients and manufacturing capacity from several countries while still depending on one critical material, intermediate, facility, or supplier. Understanding resilience requires visibility through every tier of the product supply chain.
Turn Supplier Alerts into Product-Supply Decisions
A quality alert, supplier incident, or site outage identifies where disruption began. Leaders still need to know which products, batches, markets, and clinical programs depend on that resource and what should be prioritized if supply is interrupted.
Fusion traces dependencies across key starting materials, APIs, manufacturing sites, contract partners, packaging, and distribution. Teams can determine which products and markets could be affected, evaluate alternatives, and prioritize response based on supply and patient consequences.
Four Questions Life Sciences Leaders Must Answer
Enterprise resilience is a decision problem: most large organizations cannot answer four questions at decision speed when disruption hits: what is impacted, what happens next, what is the financial exposure, and what should be prioritized first. Fusion is purpose-built to answer them.
What Is Impacted?
Which products, batches, sites, markets, and clinical programs are affected by this supplier failure, facility disruption, or quality event?
What Happens Next?
What could continue to cascade, how quickly, and which dependencies across KSMs, APIs, packaging, cold chain, and distribution could be affected next?
What Is the Financial Exposure?
What is at risk per day of disruption through lost production, diverted supply, program delays, and regulatory exposure? What is the expected cost of recovery?
What Should We Prioritize?
Given current constraints, which products, sites, suppliers, or programs should be prioritized to protect patient supply and critical timelines?
Fusion’s Approach to Life Sciences Resilience
Start with the products, sites, suppliers, and clinical programs most critical to supply and patient outcomes. Fusion’s continuously curated service-and-dependency model expands as operations, products, and priorities change.
Expose
Identify disruption exposure and third-party dependency risk across products, manufacturing operations, and clinical programs.
Model
Simulate how supplier failures, facility disruptions, quality events, and geopolitical conditions could cascade through manufacturing, distribution, and clinical operations.
Optimize
Evaluate recovery options based on patient need, product criticality, available capacity, supplier constraints, and program timelines.
Life Sciences Risk Management by Operating Model
Exposure takes a different form across pharmaceutical manufacturing, medical devices, and biotechnology. Fusion connects product and program dependencies across each operating model so teams can see where failure could affect supply, quality, and critical timelines.
Pharmaceutical Manufacturing
Concentration risk often sits upstream.
A pharmaceutical product can draw API and finished-dose production from several regions while still depending on a concentrated key starting material, intermediate, or manufacturing capability. Fusion connects KSM, API, finished-dose manufacturing, packaging, and contract-partner dependencies to specific products, sites, and markets. Teams can identify upstream chokepoints and understand how their loss could affect product supply.
Medical Devices and Diagnostics
A shared component or facility can support multiple product lines.
Fusion maps component, contract-manufacturing, quality, and distribution dependencies to devices and markets. Teams can see how a supplier, component, or facility issue could affect multiple SKUs, production lines, and regions.
Biotech and Clinical Programs
Clinical programs depend on specialized suppliers and precise timelines.
Fusion maps trial supply, cold chain, depots, laboratories, sites, and external partners to clinical programs and dosing schedules. Teams can anticipate how logistics or vendor failure could affect trial continuity, site operations, and patient timelines.
Case Study
Fusion allows us to create true end-to-end mapping of individual product families and identify risks in key categories such as tech, suppliers, equipment, and more. This is helping us take a cross-functional approach and bring silos of data together in one place to better understand our current gaps and risks and develop mitigation strategies through reporting, dashboards, and workflows.
Jennifer Park, Manager of Business Continuity, Boston Scientific Corporation
Map the Dependencies Behind Every Product
Ad hoc tracking cannot keep pace with a changing, often single-sourced supply base. Fusion maintains a continuously curated service-and-dependency model linking raw materials, suppliers, contract manufacturers, facilities, quality systems, products, and clinical programs.
Leaders gain a current view of the dependencies behind product supply and can make more informed decisions when disruption occurs.
Explore the Fusion Platform
Simulate Supplier and Manufacturing Disruption
Test scenarios across supplier concentration, facility outages, quality events, geopolitical exposure, and multi-site manufacturing disruptions. See how impact could cascade into product supply and program timelines, then compare diversification and recovery investments before an incident.
Explore Scenario Testing
Prioritize Recovery to Protect Critical Supply
Recovery decisions must account for supplier constraints, available capacity, workforce requirements, product criticality, and manufacturing dependencies. Fusion’s Recovery Optimization helps teams compare recovery sequences and determine where intervention could restore critical supply most effectively.
Explore Recovery Optimization
Keep Manufacturing and Quality Teams Ready
Fusion’s site mapping, supplier monitoring, and notification integrations help teams track exposure across facilities and suppliers, coordinate response, and maintain continuity of supply when a site, partner, or shipment is at risk.
Explore Crisis and Incident Management
FAQs
Enterprise resilience is the ability to maintain critical product supply and clinical programs through disruption. Fusion connects suppliers, sites, systems, products, and programs in a continuously curated service-and-dependency model, helping leaders quantify exposure, understand cascading impact, and prioritize recovery at decision speed.
Third-party risk management (TPRM) tools assess and monitor individual suppliers. Fusion connects supplier risk to the products, sites, batches, markets, and clinical programs that depend on them.
This allows teams to understand how a supplier or facility failure could affect product supply and determine what should be prioritized under current constraints. Fusion complements existing supplier-risk and quality programs.
Life sciences supply chains are global and multi-tiered. Geographic diversity at one tier does not eliminate concentration at another. A product may use API or finished-dose capacity from several regions while still depending on one critical KSM, intermediate, supplier, or facility.
Fusion connects those dependencies to products, sites, markets, and clinical programs so teams can identify concentration risk and prepare response options before supply is interrupted.
Fusion helps teams maintain dependency maps, recovery plans, scenario records, exercise results, and after-action evidence that can support internal governance and regulatory readiness. Quality and GRC platforms remain the authoritative systems for quality records, audit findings, and regulated documentation.
Fusion connects that information to operational dependencies so leaders can understand disruption impact and coordinate response.
Yes. Fusion integrates with systems life sciences organizations already use, including ERP, MES, CMDB, GRC, quality platforms, and supplier-monitoring feeds. It brings relevant data into a governed service-and-dependency model that connects operational records to products, sites, suppliers, and clinical programs.
Protect Product Supply Through Disruption
See how Fusion helps life sciences organizations connect critical dependencies, prepare for disruption, and prioritize recovery across products, manufacturing operations, and clinical programs.